These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17707537)

  • 1. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
    Söderlund K; Skoog L; Fornander T; Askmalm MS
    Radiother Oncol; 2007 Sep; 84(3):242-51. PubMed ID: 17707537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA repair gene expression and risk of locoregional relapse in breast cancer patients.
    Le Scodan R; Cizeron-Clairac G; Fourme E; Meseure D; Vacher S; Spyratos F; de la Lande B; Cvitkovic F; Lidereau R; Bieche I
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):328-36. PubMed ID: 20092964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
    Chen JJ; Silver D; Cantor S; Livingston DM; Scully R
    Cancer Res; 1999 Apr; 59(7 Suppl):1752s-1756s. PubMed ID: 10197592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
    Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
    Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in the RAD51 gene and familial breast cancer.
    Lose F; Lovelock P; Chenevix-Trench G; Mann GJ; Pupo GM; Spurdle AB;
    Breast Cancer Res; 2006; 8(3):R26. PubMed ID: 16762046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
    Cousineau I; Abaji C; Belmaaza A
    Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer.
    Nowacka-Zawisza M; Bryś M; Romanowicz-Makowska H; Kulig A; Krajewska WM
    Cancer Detect Prev; 2008; 32(2):144-8. PubMed ID: 18632222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of HuR in hereditary breast cancer.
    Heinonen M; Fagerholm R; Aaltonen K; Kilpivaara O; Aittomäki K; Blomqvist C; Heikkilä P; Haglund C; Nevanlinna H; Ristimäki A
    Clin Cancer Res; 2007 Dec; 13(23):6959-63. PubMed ID: 18056170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.
    Ding SL; Yu JC; Chen ST; Hsu GC; Kuo SJ; Lin YH; Wu PE; Shen CY
    Carcinogenesis; 2009 Jan; 30(1):43-9. PubMed ID: 18974064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
    Gal I; Kimmel G; Gershoni-Baruch R; Papa MZ; Dagan E; Shamir R; Friedman E
    Eur J Cancer; 2006 May; 42(8):1129-34. PubMed ID: 16624550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer.
    Romanowicz-Makowska H; Smolarz B; Kulig A
    Pol J Pathol; 2005; 56(4):161-5. PubMed ID: 16477874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.
    Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Int J Oncol; 2009 Feb; 34(2):441-8. PubMed ID: 19148479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Rad51 alteration in patients with bilateral breast cancer.
    Kato M; Yano K; Matsuo F; Saito H; Katagiri T; Kurumizaka H; Yoshimoto M; Kasumi F; Akiyama F; Sakamoto G; Nagawa H; Nakamura Y; Miki Y
    J Hum Genet; 2000; 45(3):133-7. PubMed ID: 10807537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.